Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease

Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease

Abstract Introduction This study explored the safety and tolerability features of donanemab (LY3002813) in patients with mild cognitive impairment due to Alzheimer's disease (AD) or mild to moderate AD dementia. Methods Patients with AD were enrolled into the single‐ascending dose phase and wer...

Full description

Bibliographic Details
Main Authors: Stephen Loucian Lowe, Brian A. Willis, Anne Hawdon, Fanni Natanegara, Laiyi Chua, Joanne Foster, Sergey Shcherbinin, Paul Ardayfio, John R. Sims
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
Alzheimer's disease
dementia
donanemab
mild to moderate
tolerability
Online Access:https://doi.org/10.1002/trc2.12112

Internet

https://doi.org/10.1002/trc2.12112

Similar Items